Benjamin Holmes, DVM | Authors

Articles

Interleukin-Based Treatments Find Footing in Ongoing Research

August 16, 2022

Current- generation cytokines are being engineered to extend their half-life and improve tumor targeting using polyethylene glycol conjugation, fusion to tumor-targeting antibodies, alterations of cytokine/cell receptor–binding affinity, and other strategies.